Payment overview · 2025
General Payments
$979.52
45 reported records · 15 companies
Healthcare provider profile · identity verified
Zachary Thomas Brown, MD
Allopathic & Osteopathic Physicians|Family Medicine · MAYER, AZ · NPI 1669094173
Verified facts
What the public records show
CMS Open Payments records show Zachary Thomas Brown, MD received $979.52 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.28 | 28.1% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.02 | 9.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.52 | 8.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.65 | 7.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.23 | 6.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $61.25 | 6.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.30 | 6.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.46 | 6.0% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $52.90 | 5.4% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $51.47 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.23 | 4.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $24.33 | 2.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $21.59 | 2.2% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $18.48 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.81 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $979.52 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $173.38 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $107.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.90 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.02 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $78.52 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.23 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.30 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.46 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $52.90 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $51.49 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $51.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 154 | 76 |
| Lisinopril | Lisinopril | 145 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 57 |
| Gabapentin | Gabapentin | 128 | 56 |
| Omeprazole | Omeprazole | 102 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 74 | 36 |
| Losartan Potassium | Losartan Potassium | 74 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 32 |
| Prednisone | Prednisone | 69 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 29 |
| Tramadol Hcl | Tramadol Hcl | 63 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 26 |
| Sertraline Hcl | Sertraline Hcl | 52 | 19 |
| Trazodone Hcl | Trazodone Hcl | 52 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 43 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 48 | 21 |
| Metformin Hcl | Metformin Hcl | 46 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 21 |
| Montelukast Sodium | Montelukast Sodium | 43 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 17 |
| Pregabalin | Pregabalin | 43 | 20 |
| Meloxicam | Meloxicam | 42 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 17 |
| Naproxen | Naproxen | 41 | 31 |
| Eliquis | Apixaban | 40 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 21 |
| Farxiga | Dapagliflozin Propanediol | 36 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 21 |
| Ozempic | Semaglutide | 36 | 11 |
| Mirtazapine | Mirtazapine | 35 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 19 |
| Simvastatin | Simvastatin | 35 | 18 |
| Baclofen | Baclofen | 34 | 21 |
| Furosemide | Furosemide | 34 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 13 |
| Buspirone Hcl | Buspirone Hcl | 33 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 17 |
| Famotidine | Famotidine | 29 | 17 |
| Hydrocortisone | Hydrocortisone | 29 | 19 |
| Azithromycin | Azithromycin | 28 | 26 |
| Potassium Chloride | Potassium Chloride | 28 | 14 |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | 11 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 16 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | 16 |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 16 |
| Allopurinol | Allopurinol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | 11 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | 11 |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $979.52 · 45 records | AstraZeneca Pharmaceuticals LP | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ABRYSVO, AIRSUPRA, BREZTRI, BRIXADI, CAPLYTA, COBENFY, COMIRNATY, FARXIGA, JOURNAVX, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, MAVYRET, MOUNJARO, PREVNAR 20, QULIPTA, SUBLOCADE, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error